In recent years, as the volume of chest CT scans across the population has risen markedly in the wake of the pandemic,the detection rate of pulmonary nodules has climbed sharply, and with it the detection of early-stage lung cancer. This means the true era of lung health management has arrived:
More people are thrown into anxiety by a nodule spotted at a routine check-up — and more patients with early disease are being given a chance to be saved.
Yet telling benign nodules from malignant ones is difficult, follow-up pathways are unclear, and excessive anxiety coexists with blind optimism— a challenge over how to manage lung risk more scientifically is quietly taking shape.
November each year is International Lung Cancer Awareness Month, and the 2025 theme is:"Value early lung cancer screening; standardise clinical diagnosis and treatment". This global health initiative was established to call on governments, healthcare institutions and the public to raise awareness of lung cancer prevention, strengthen early screening capacity, and put standardised diagnosis, treatment and long-term management into practice.
Why must we keep paying attention to lung cancer?
● Early disease is almost symptom-free and easily overlooked
● LDCT is the gold standard, yet coverage and adherence remain poor
● Tumour markers have limited sensitivity and weak ability to identify early disease
● Many postoperative patients still have the same question:
"Will it come back? When will it come back? Can it be known in advance?"
Both early screening and postoperative management urgently need tools that are more precise and positioned earlier.
We are not only calling for attention; we also bring two answers from the front line of technology:one for earlier detection, one for longer-lasting peace of mind.
Elixir-LuCa™: one step earlier,
capturing hidden risk
When CT scans make people hesitate because of radiation and cost, and when tumour markers struggle to pick up early lesions, sharper tools matter more than ever.
The answer lies in "a tube of blood" —
The Elixir-LuCa™ lung cancer screening service is redefining the boundaries of early screening.
● More forward-looking: a large-model advantage in data scale
Built on plasma data from more than 160,000 people and an AI model with a Transformer architecture, it works like a tireless "AI detective", identifying early risk amid vast numbers of molecular signals.
● More reassuring: high discriminative power, less unnecessary alarm
Overall discriminative ability (AUC) ≥ 96.7%, substantially reducing the psychological burden that misclassification brings and making screening results more trustworthy.
● Lighter touch: non-invasive, fast and radiation-free
- No fasting required, and the process is simple
- Requires less than 0.5 mL of plasma
- Reports issued within 5-7 working days
▍ From "worried something is wrong" to "confirmed nothing is wrong" — LuCa™ makes preventive screening a calm, sustainable habit.
PT-L1™: one step further, foreseeing the road to recovery
After successful surgery, "will it come back?" is the greatest anxiety of every patient with stage I lung cancer. Conventional tools cannot predict it precisely, and by the time relapse occurs, about 30% of patients have already missed the optimal window for intervention.
The answer lies in "a piece of tissue" —
The ProteinT-Lung1™ (PT-L1™) postoperative recurrence risk prediction system moves postoperative management into the era of "predictive medicine".
● More precise: striking at the molecular essence of recurrence
Overall discriminative ability reaches an AUC of 0.89 (95% CI: 0.85-0.94), offering clear clinical value in postoperative risk stratification.
● More personalised: genuine risk-stratified management
It provides doctors with an evidence base for decisions, supporting personalised follow-up plans — early intervention for high-risk patients, no unnecessary burden for low-risk ones.
● More credible: a solid clinical and compliance foundation
Validated clinically in more than 700 patients, and now applying for the national fast-track review pathway for innovative medical devices, it represents the leading edge of precision medicine for lung cancer in China.
▍ From "anxious uncertainty" to "a clearly defined path" — PT-L1™ makes the road to recovery more controllable and more visible.
This Lung Cancer Awareness Month, We Invite You to Do Three Things
● Pass on what you know
Share the ideas of "early screening" and "precision prognosis" with the people who need them.
● Look out for those at high risk around you
Remind friends with a family history, long-term smokers or people in high-risk environments to have a scientific screening once a year.
● Embrace precision medicine
Learn how LuCa™ and PT-L1™ use the power of technology to safeguard the respiratory health of you and your family.
Lung cancer is silent; technology is not.Elixir-LuCa™ and PT-L1™ are making early screening more accessible, follow-up more precise and intervention more timely. This 2025 Lung Cancer Awareness Month, may everyone have access to earlier, steadier and more certain answers about their health.
